Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Effects of Rifaximin on Circulating Aged Neutrophils in Sickle Cell Disease
source: American Journal of Hematology
year: 2019
authors: Dutta D, Methe BA, Morris A, Lim SH
summary/abstract:There is a large therapeutic gap in sickle cell disease (SCD). Hydroxy-urea reduces acute sickle cell-related events, but does not appear to protect patients from cardiopulmonary complications, which are the major causes of death in SCD patients. The long-term effects of newer agents such as crizanlizumab and L-glutamine on the disease course remain to be determined. The only cure currently available for SCD is allogeneic stem cell transplant (allo-SCT); however, many barriers prevent allo-SCT from being readily offered to these patients. Investigations into other therapeutic approaches are, therefore, appropriate.
Activated and circulating aged neutrophils (CANs) adhere to vascular endothelium and are pivotal for the pathogenesis of sickle cell vaso-occlusive crisis (VOC). CANs in mice are regulated by intestinal micro biota. Treatment of SCD mice with a cocktail of ampicillin, neomycin, metronidazole, and vancomycin (ANMV) induced reduction in CANs and protected the mice from fatal tumor necrosis factor-α-induced VOC. Therefore, antibiotic therapy might be a potential therapeutic approach for SCD.
organization: New York Medical College, USA; University of Pittsburgh, USADOI: 10.1002/ajh.25467
read more full text
+myBinderRelated Content
-
Big Jump in Success for Sickle Cell TransplantsDoubling the dose of total-body irradiat...
-
A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Seve...Background: Children with severe sickle...
-
Georgia Universities Join NIH-funded National Study of Bone Marrow Transplant for SCDThe Medical College of Georgia (MCG) and...
-
Discovery First in Human: Bringing Awareness of Sickle Cell Diseasehttps://www.youtube.com/watch?v=kffu_YvJ...
-
Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA u...Advances in allogeneic hematopoietic cel...
-
Sickle cell cure is real, as this Kansas patient provesIntense pain. Fatigue. Repeated infectio...
-
A Child Prodigy, a Painful Disease, and a Life-Changing Treatmenthttps://www.youtube.com/watch?v=SpzjD1ct...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.